Blurbs

Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Ascendis Pharma (ASND) and GT Biopharma (GTBP)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAXResearch Report), Ascendis Pharma (ASNDResearch Report) and GT Biopharma (GTBPResearch Report) with bullish sentiments.

Dynavax (DVAX)

H.C. Wainwright analyst Edward White reiterated a Buy rating on Dynavax today and set a price target of $28.00. The company’s shares closed last Monday at $11.78.

According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -16.0% and a 30.4% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Dynavax with a $26.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Ascendis Pharma (ASND)

Wedbush analyst Andreas Argyrides reiterated a Buy rating on Ascendis Pharma today and set a price target of $127.00. The company’s shares closed last Monday at $103.61.

According to TipRanks.com, Argyrides ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.9% and a 23.3% success rate. Argyrides covers the Healthcare sector, focusing on stocks such as Rani Therapeutics Holdings, Global Blood Therapeutics, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $147.00, which is a 43.9% upside from current levels. In a report issued on August 29, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $166.00 price target.

GT Biopharma (GTBP)

H.C. Wainwright analyst Robert Burns reiterated a Buy rating on GT Biopharma today and set a price target of $5.00. The company’s shares closed last Monday at $2.43, close to its 52-week low of $1.51.

According to TipRanks.com, Burns ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -16.2% and a 27.2% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Black Diamond Therapeutics, and Springworks Therapeutics.

Currently, the analyst consensus on GT Biopharma is a Moderate Buy with an average price target of $4.00.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on DVAX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos